## Esen K Akpek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1292921/publications.pdf

Version: 2024-02-01

94433 51608 8,306 127 37 86 citations h-index g-index papers 131 131 131 7020 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of <scp>Diseaseâ€Modifying</scp> Therapies. Arthritis Care and Research, 2022, 74, 1559-1565.	3.4	11
2	Reliability of Several Glaucoma Tests in Patients With Boston Type 1 Keratoprosthesis. Cornea, 2022, 41, 310-316.	1.7	4
3	Outcome Measures to Assess Dry Eye Severity: A Review. Ocular Immunology and Inflammation, 2022, 30, 282-289.	1.8	2
4	A comprehensive overview of living with Sjögren's: results of a National Sjögren's Foundation survey. Clinical Rheumatology, 2022, 41, 2071-2078.	2.2	4
5	Reduced tear thrombospondinâ€1/matrix metalloproteinaseâ€9 ratio can aid in detecting Sjögren's syndrome etiology in patients with dry eye. Clinical and Translational Science, 2022, 15, 1999-2009.	3.1	4
6	National Sjögren's Foundation Survey: Burden of Oral and Systemic Involvement on Quality of Life. Journal of Rheumatology, 2021, 48, 1029-1036.	2.0	10
7	Cicatrizing conjunctivitis as an uncommon manifestation of primary Sjögren's syndrome. Ocular Surface, 2021, 19, 38-42.	4.4	4
8	Neuropathic Pain in the Eyes, Body, and Mouth: Insights from the Sjögren's International Collaborative Clinical Alliance. Pain Practice, 2021, 21, 630-637.	1.9	2
9	Impact of COVID-19 Pandemic on Infectious Keratitis Outcomes: A Retrospective Multicenter Study in Tertiary Eye Hospitals of South India. Cornea, 2021, 40, 1474-1481.	1.7	7
10	Autologous serum eye drops for ocular surface disorders. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 493-499.	2.3	14
11	Impact of the COVID-19 pandemic on eye strain and dry eye symptoms. Ocular Surface, 2021, 22, 38-46.	4.4	33
12	Surgeon Preference for Keratoplasty Techniques and Barriers to Performing Deep Anterior Lamellar Keratoplasty. Cornea, 2021, 40, 1406-1412.	1.7	12
13	A New Screening Questionnaire to Identify Patients With Dry Eye With a High Likelihood of Having Sjögren Syndrome. Cornea, 2021, 40, 179-187.	1.7	4
14	Characterization of Progressive Cicatrizing Conjunctivitis With Negative Immunofluorescence Staining. American Journal of Ophthalmology, 2020, 209, 3-9.	3.3	5
15	Sustained Gazing Causes Measurable Decline in Visual Function of Patients with Dry Eye. American Journal of Ophthalmology, 2020, 210, 107-115.	3 <b>.</b> 3	6
16	Differential Diagnosis of Sjögren Versus Non-Sjögren Dry Eye Through Tear Film Biomarkers. Cornea, 2020, 39, 991-997.	1.7	17
17	Ocular Clinical Signs and Diagnostic Tests Most Compatible With Keratoconjunctivitis Sicca: A Latent Class Approach. Cornea, 2020, 39, 1013-1016.	1.7	17
18	Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. PLoS ONE, 2020, 15, e0239769.	2.5	8

#	Article	IF	CITATIONS
19	Artificial corneas versus donor corneas for repeat corneal transplants. The Cochrane Library, 2020, 2020, CD009561.	2.8	6
20	Ocular Manifestations and Burden Related to Sjögren Syndrome: Results of a Patient Survey. American Journal of Ophthalmology, 2020, 219, 40-48.	3.3	15
21	Concurrent primary Sjögren's syndrome and isolated ocular sarcoidosis presenting with bilateral corneal scarring and dry eye. American Journal of Ophthalmology Case Reports, 2020, 19, 100790.	0.7	1
22	Gender-Specific Trends in Ophthalmologist Medicare Collections. American Journal of Ophthalmology, 2020, 214, 32-39.	3.3	16
23	The negative effects of dry eye disease on quality of life and visual function. Turkish Journal of Medical Sciences, 2020, 50, 1611-1615.	0.9	15
24	"Ray of light during tough timesâ€â€"Role of gamma irradiated corneal tissue in emergency keratoplasty. Indian Journal of Ophthalmology, 2020, 68, 2310.	1.1	3
25	Short-Term Clinical Outcomes of a Novel Corneal Prosthetic Device in a Rabbit Model. Cornea, 2020, 39, 706-712.	1.7	4
26	Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology, 2019, 126, P286-P334.	5 <b>.</b> 2	108
27	Conjunctivitis Preferred Practice Pattern®. Ophthalmology, 2019, 126, P94-P169.	5.2	65
28	Corneal Ectasia Preferred Practice Pattern®. Ophthalmology, 2019, 126, P170-P215.	5.2	32
29	Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology, 2019, 126, P1-P55.	5.2	157
30	Blepharitis Preferred Practice Pattern®. Ophthalmology, 2019, 126, P56-P93.	5 <b>.</b> 2	79
31	Corneal Edema and Opacification Preferred Practice Pattern®. Ophthalmology, 2019, 126, P216-P285.	5.2	20
32	Clinical Correlations of Novel Autoantibodies in Patients with Dry Eye. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	11
33	Topical cyclosporine A therapy for dry eye syndrome. The Cochrane Library, 2019, 9, CD010051.	2.8	65
34	Long-term clinical outcomes of keratoplasty using gamma-irradiated corneal lenticules. BMJ Open Ophthalmology, 2019, 4, e000396.	1.6	15
35	Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. The Cochrane Library, 2019, 12, CD011016.	2.8	42
36	Sjögren's Syndrome: More Than Just Dry Eye. Cornea, 2019, 38, 658-661.	1.7	83

#	Article	IF	CITATIONS
37	Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups. Ophthalmology, 2019, 126, 6-9.	5.2	14
38	Utility of Novel Autoantibodies in the Diagnosis of SjĶgren's Syndrome Among Patients With Dry Eye. Cornea, 2018, 37, 405-411.	1.7	20
39	Effects of Prolonged Reading on Dry Eye. Ophthalmology, 2018, 125, 1500-1505.	5.2	27
40	Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. Arthritis Care and Research, 2018, 70, 284-294.	3.4	43
41	Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Cornea, 2018, 37, 248-251.	1.7	34
42	Impact of Dry Eye on Prolonged Reading. Optometry and Vision Science, 2018, 95, 1105-1113.	1.2	28
43	Validation of an Objective Measure of Dry Eye Severity. Translational Vision Science and Technology, 2018, 7, 26.	2.2	8
44	Research Questions and Outcomes Prioritized by Patients With Dry Eye. JAMA Ophthalmology, 2018, 136, 1170.	2.5	40
45	Etiology of Global Corneal Blindness and Current Practices of Corneal Transplantation: A Focused Review. Cornea, 2018, 37, 1198-1203.	1.7	92
46	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 9-16.	0.9	959
47	Functional impairment of reading in patients with dry eye. British Journal of Ophthalmology, 2017, 101, 481-486.	3.9	47
48	Autologous serum eye drops for dry eye. The Cochrane Library, 2017, 2017, CD009327.	2.8	75
49	Gaps in Current Knowledge and Priorities for Future Research in Dry Eye. Cornea, 2017, 36, 1584-1591.	1.7	15
50	Tear Osmolarity and Correlation With Ocular Surface Parameters in Patients With Dry Eye. Cornea, 2017, 36, 1352-1357.	1.7	21
51	TFOS DEWS II Introduction. Ocular Surface, 2017, 15, 269-275.	4.4	180
52	TFOS DEWS II Definition and Classification Report. Ocular Surface, 2017, 15, 276-283.	4.4	1,932
53	610 Increased LL-37 and KLK5 expression in conjunctival epithelium associated with ocular rosacea severity. Journal of Investigative Dermatology, 2017, 137, S105.	0.7	0
54	Impact of Glaucoma and Dry Eye on Text-Based Searching. Translational Vision Science and Technology, 2017, 6, 24.	2.2	12

#	Article	IF	Citations
55	A validated method of labial minor salivary gland biopsy for the diagnosis of Sjögren's syndrome. Laryngoscope, 2016, 126, 2041-2046.	2.0	16
56	Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 150-154.	1.4	7
57	Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis $\hat{a} \in ``A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. Ocular Surface, 2016, 14, 168-188.$	4.4	163
58	The Usage of a Conjunctival Flap to Improve Retention of Boston Type 1 Keratoprosthesis in Severe Ocular Surface Disease. Ocular Immunology and Inflammation, 2016, 24, 555-560.	1.8	6
59	Association of Dry Eye Tests With Extraocular Signs Among 3514 Participants in the Sjögren's Syndrome International Registry. American Journal of Ophthalmology, 2016, 172, 87-93.	3.3	26
60	Treating Infectious Keratitis. Ocular Immunology and Inflammation, 2016, 24, 479-481.	1.8	3
61	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis – A Comprehensive Review and Guide to Therapy. I. Systemic Disease. Ocular Surface, 2016, 14, 2-19.	4.4	112
62	Sarcoidosis Presenting with Cicatrizing Conjunctivitis. Optometry and Vision Science, 2015, 92, e173-e175.	1.2	8
63	Predictors of Visual Outcomes Following Boston Type 1 Keratoprosthesis Implantation. American Journal of Ophthalmology, 2015, 159, 739-747.e1.	3.3	26
64	Ocular Complications of Primary Sj $\tilde{A}$ ¶gren Syndrome in Men. American Journal of Ophthalmology, 2015, 160, 447-452.e1.	3.3	33
65	Evaluation of Broadband Spectral Transmission Characteristics of Fresh and Gamma-Irradiated Corneal Tissues. Cornea, 2015, 34, 228-234.	1.7	12
66	Inter-grader Agreement of the Ocular Staining Score in the Sjögren's International Clinical Collaborative Alliance (SICCA) Registry. American Journal of Ophthalmology, 2015, 160, 1150-1153.e3.	3.3	32
67	Donor Corneal Transplantation vs Boston Type 1 Keratoprosthesis in Patients with Previous Graft Failures: A Retrospective Single Center Study (An American Ophthalmological Society Thesis). Transactions of the American Ophthalmological Society, 2015, 113, T3.	1.4	6
68	Artificial corneas versus donor corneas for repeat corneal transplants. The Cochrane Library, 2014, , CD009561.	2.8	21
69	Sarcoidosis Presenting as Scleral Nodule. Ocular Immunology and Inflammation, 2014, 22, 311-313.	1.8	7
70	No Increase in IgG4-positive Plasma Cells in Limbal Rosai–Dorfman Disease. Cornea, 2014, 33, 844-847.	1.7	6
71	Association of Dry Eye and Inflammatory Systemic Diseases in a Tertiary Care–Based Sample. Cornea, 2014, 33, 819-825.	1.7	44
72	Impact of dry eye on reading in a population-based sample of the elderly: the Salisbury Eye Evaluation. British Journal of Ophthalmology, 2014, 98, 639-644.	3.9	31

#	Article	IF	Citations
73	Omega-3 and omega-6 polyunsaturated fatty acids for dry eye syndrome. The Cochrane Library, 2014, , .	2.8	7
74	Necrotizing scleritis as a complication of cosmetic eye whitening procedure. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 39.	2.2	16
75	Evaluation of Ocular Surface Disease in Patients with Glaucoma. Ophthalmology, 2013, 120, 2241-2248.	5.2	69
76	Autologous serum eye drops for dry eye. , 2013, , CD009327.		89
77	Overview of age-related ocular conditions. American Journal of Managed Care, 2013, 19, S67-75.	1.1	25
78	Current treatment strategies for age-related ocular conditions. American Journal of Managed Care, 2013, 19, S76-84.	1.1	3
79	Ocular graft-versus-host disease. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 540-547.	2.3	104
80	Mucous membrane pemphigoid. Current Opinion in Ophthalmology, 2012, 23, 523-527.	2.9	14
81	Travmatik Kök Hücre Yetmezliği ve Keratoplasti Reddinde Boston Tip 1 Keratoprotez İmplantasyonu. Türk Oftalmoloji Dergisi, 2012, 42, 66-71.	0.9	0
82	Topical Calcineurin Inhibitors in the Treatment of Steroid-Dependent Atopic Keratoconjunctivitis. Cornea, 2012, 31, 649-654.	1.7	23
83	Interventions for chronic blepharitis. The Cochrane Library, 2012, , CD005556.	2.8	83
84	Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. British Journal of Ophthalmology, 2012, 96, 1498-1503.	3.9	83
85	Chronic Hypotony Associated With the Boston Type 1 Keratoprosthesis. American Journal of Ophthalmology, 2012, 154, 266-271.e1.	3.3	30
86	The Use of Precut, $\hat{I}^3$ -Irradiated Corneal Lenticules in Boston Type 1 Keratoprosthesis Implantation. American Journal of Ophthalmology, 2012, 154, 495-498.e1.	3.3	31
87	American College of Rheumatology classification criteria for Sjögren's syndrome: A dataâ€driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care and Research, 2012, 64, 475-487.	3.4	1,127
88	Clinical Features and Prognosis of Boston Type I Keratoprosthesis-associated Corneal Melt. Ocular Immunology and Inflammation, 2011, 19, 413-418.	1.8	39
89	Visual and clinical outcomes of explantation versus preservation of the intraocular lens during keratoprosthesis implantation. Journal of Cataract and Refractive Surgery, 2011, 37, 1615-1622.	1.5	13
90	The Intraoperative Impression and Postoperative Outcomes of Gamma-Irradiated Corneas in Corneal and Glaucoma Patch Surgery. Cornea, 2011, 30, 1387-1391.	1.7	53

#	Article	IF	Citations
91	The International Workshop on Meibomian Gland Dysfunction: Report of the Clinical Trials Subcommittee., 2011, 52, 2065.		54
92	Permanent Keratoprosthesis Combined With Pars Plana Vitrectomy and Silicone Oil Injection for Visual Rehabilitation of Chronic Hypotony and Corneal Opacity. Cornea, 2010, 29, 1401-1405.	1.7	26
93	Evaluation of Patients With Dry Eye for Presence of Underlying Sjögren Syndrome. Cornea, 2010, 29, 1073.	1.7	0
94	Use of a Microvascular Clip for Iris Fixation of an Intraocular Lens. JAMA Ophthalmology, 2010, 128, 114.	2.4	4
95	Crescenteric Amniotic Membrane Grafting in Keratoprosthesis-Associated Corneal Melt. JAMA Ophthalmology, 2010, 128, 779.	2.4	25
96	Noninvasive volumetric quality evaluation of post-surgical clear corneal incision via high-resolution Fourier-domain optical coherence tomography. Electronics Letters, 2010, 46, 1482.	1.0	1
97	Clinical Review: Topical Ophthalmic Use of Cyclosporin A. Ocular Immunology and Inflammation, 2010, 18, 352-361.	1.8	126
98	Autoimmune hepatitis in patients with primary Sjögren's syndrome: a series of two-hundred and two patients. International Journal of Clinical and Experimental Pathology, 2010, 3, 582-6.	0.5	18
99	Glaucoma and Dry Eye. Ophthalmology, 2009, 116, 1232.	5.2	18
100	Medical management of acutely recurring pterygium with topical mitomycin-C. Journal of Cataract and Refractive Surgery, 2009, 35, 200-202.	1.5	1
101	Occult Thyroid Eye Disease in Patients Presenting with Dry Eye Symptoms. American Journal of Ophthalmology, 2009, 147, 919-923.	3.3	92
102	Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 433-440.	1.4	64
103	Evaluation of Patients With Dry Eye for Presence of Underlying Sjögren Syndrome. Cornea, 2009, 28, 493-497.	1.7	114
104	Sterile Corneal Melt After Descemet Stripping Endothelial Keratoplasty in Patients With Previously Undiagnosed Sjögren Syndrome. JAMA Ophthalmology, 2009, 127, 219.	2.4	24
105	Gatifloxacin ophthalmic solution 0.3% in the treatment of bacterial keratitis. Expert Review of Ophthalmology, 2008, 3, 21-27.	0.6	0
106	Autoimmune Th2-Mediated Dacryoadenitis in MRL/MpJ Mice Becomes Th1-Mediated in IL-4 Deficient MRL/MpJ Mice., 2007, 48, 5624.		13
107	Pediatric Keratoprosthesis. Ophthalmology, 2007, 114, 989-994.	5.2	100
108	Histopathologic and Immunologic Aspects of AlphaCor Artificial Corneal Failure. American Journal of Ophthalmology, 2007, 144, 699-704.e4.	3.3	24

#	Article	IF	Citations
109	Isolated lichen planus of the conjunctiva. British Journal of Ophthalmology, 2006, 90, 1325-1326.	3.9	26
110	Subluxation of Iris-Sutured Intraocular Lenses and Results of a Closed Chamber Technique for Repositioning After Penetrating Keratoplasty. Cornea, 2005, 24, 438-442.	1.7	5
111	Current concepts and techniques in keratoprosthesis. Current Opinion in Ophthalmology, 2005, 16, 246-250.	2.9	72
112	IMMUNOSUPPRESSION FOR POSTERIOR UVEITIS. Retina, 2005, 25, 1-18.	1.7	51
113	Topical ciclosporin in the treatment of ocular surface disorders. British Journal of Ophthalmology, 2005, 89, 1363-1367.	3.9	100
114	Chemokines in Autoimmune Lacrimal Gland Disease in MRL/MpJ Mice., 2004, 45, 185.		25
115	Immune defense at the ocular surface. Eye, 2003, 17, 949-956.	2.1	109
116	New treatments for serpiginous choroiditis. Current Opinion in Ophthalmology, 2003, 14, 128-131.	2.9	30
117	Endothelial dystrophy, iris hypoplasia, congenital cataract, and stromal thinning (edict) syndrome maps to chromosome 15q22.1–q25.3. American Journal of Ophthalmology, 2002, 134, 172-176.	3.3	20
118	Identification of paramyosin as a binding protein for calgranulin C in experimental helminthic keratitis. Investigative Ophthalmology and Visual Science, 2002, 43, 2677-84.	3.3	25
119	Spontaneous corneal perforation in a patient with unusual unilateral pellucid marginal degeneration. Journal of Cataract and Refractive Surgery, 2001, 27, 1698-1700.	1.5	29
120	Long-term immunosuppressive treatment of serpiginous choroiditis. Ocular Immunology and Inflammation, $2001, 9, 153-167$ .	1.8	58
121	Unusual Locations for Lymphomas. Journal of Clinical Oncology, 2001, 19, 2964-2966.	1.6	1
122	Choroidopathy of systemic lupus erythematosus. Lupus, 2000, 9, 288-298.	1.6	116
123	Mitomycin-C and vernal conjunctivitis: Author's reply. Ophthalmology, 2000, 107, 2127.	5.2	0
124	Peripheral ulcerative keratitis after clear corneal cataract extraction. Journal of Cataract and Refractive Surgery, 2000, 26, 1424-1427.	1.5	23
125	Bilateral acute retinal necrosis caused by cytomegalovirus in an immunocompromised patient. American Journal of Ophthalmology, 1999, 127, 93-95.	3.3	23
126	Ocular Surface Neoplasia Masquerading as Chronic Blepharoconjunctivitis. Cornea, 1999, 18, 282.	1.7	51

#	Article	IF	CITATIONS
127	Krill Protease Effects on Wound Healing After Corneal Alkali Burn. Cornea, 1999, 18, 707.	1.7	14